Merck to axe 1,200 sales jobs

Share this article:
Merck makes a play for generic biologics market
Merck makes a play for generic biologics market

Merck announced plans to cut 1,200 sales jobs in the US. Affected employees will be notified by the end of May, with "separations...completed by the end of July," according to a company statement.

“Merck is taking this step as part of our previously disclosed, continuing efforts to optimize our cost base and improve Merck's effectiveness and efficiency across all aspects of our business as part of our Plan to Win strategy,” said Kenneth Frazier, president, Global Human Health. “With eight successful launches of Merck products approved in the US since 2006 now behind us, and with an unexpected delay in a new product approval, we decided to accelerate the achievement of efficiencies we anticipate gaining as we transition to our new commercial model in the US.”

The FDA's recent rejection of Merck's cholesterol drug Cordaptive, to be packaged with Zocor, came as a surprise to analysts. Additionally, Vytorin sales dropped during the first quarter amidst ENHANCE controversy.

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union